Gleiss Lutz has advised Boehringer Ingelheim on its long-term cooperation with ViraTherapeutics as well as an option to acquire the company after completion of phase I clinical testing. The deal is valued at up to EUR 210 million.
ViraTherapeutics GmbH is a privately owned biopharmaceutical firm based in Innsbruck, Austria, that develops innovative virus-based immunotherapeutics for the treatment of cancer. The aim of the collaboration is to jointly develop oncolytic viruses, one of the most promising new therapy approaches in cancer research. The Boehringer Ingelheim Venture Fund (BIVF) is already one of the Austrian firm’s core investors.
Boehringer Ingelheim is one of the top 20 leading pharmaceutical companies in the world. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 47,500 employees.
Boehringer Ingelheim was advised by a Gleiss Lutz team headed by Dr. Alexander Schwarz (lead, partner, corporate/M&A, Düsseldorf), Dr. Herwig Lux (counsel, IP, Stuttgart) and Dr. Martin Viciano Gofferje (counsel, corporate/M&A, Berlin) and which included the following lawyers: Bernhard Barth (corporate/M&A, Berlin) and Dr. Hendrik Marchal (tax, Hamburg).
Maybach Görg Lenneis Geréd Rechtsanwälte GmbH advised on Austrian law.
Dr. Jan Bolt from Boehringer Ingelheim’s corporate legal department acted as lead counsel on the transaction.
Gleiss Lutz is regularly involved in prominent and landmark cases in the healthcare sector. To this end it combines the industry-specific expertise and knowledge of specialists from a wide range of legal fields. In addition to advising clients on complex transactions, Gleiss Lutz is also involved in current legislative procedures in the healthcare sector. Moreover, it successfully represents major pharmaceutical and medicinal products manufacturers in patent-related disputes.
Forward
